Diagnostic Value of Serum Cytokeratin 8, 18 and 19 in Lung Cancer

Chang Min Choi, Woo Jin Kim, Jin Young Oh, youngae kang, Chul Gyu Yoo, Choon Taek Lee, Young Whan Kim, Sung Koo Han, Young Soo Shim

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: Monoclonal antibodies directed against well-known epitopes on cytokeratin (CK) 8, 18 and 19 (Monototal) have been used in the development of a new diagnostic tool for lung cancer. In the mid-1990s, CK 19 fragments (Cyfra 21-1) became popular and widely used for such diagnosis. This is the first study specifically designed to compare these two markers. Method: The serum levels of CK 8, 18 and 19 were measured using two-site monoclonal/polyclonal immunoradiometric assay kit in 57 healthy adults and 289 patients who were admitted to Seoul National University Hospital from May to September, 2002. The lung cancer group comprised 129 primary lung cancer patients; 116 with non-small cell lung cancer(NSCLC) and 13 with small cell lung cancer (SCLC). The control group comprised 160 non-malignant pulmonary lung disease patients and 57 healthy adults. A total of 166 twin Monototal and Cyfra 21-1 serum assays were obtained; 76 with lung cancer, 70 with non-malignant pulmonary lung disease and 20 healthy adults. Results: The mean serum value of Monototal was 412.47 ± 455.45U/L in NSCLC, 237.08 ± 145.15U/L in SCLC, 126.54 ± 95.72U/L in non-malignant pulmonary lung disease, and 63.68 ± 31.66U/L in healthy adults. The serum values of the lung cancer groups were significantly higher than those of the control group (p < 0.01). Using a cut off value of 188U/L, sensitivity and specificity was 66.4% and 81.9% in NSCLC, and 43.8% and 81.9% in SCLC, respectively. The serum levels of CK 8, 18 and 19 were higher in advanced NSCLC than in early stage disease. Conclusion: The serum levels of CK 8, 18 and 19 may be useful in the diagnosis of NSCLC.

Original languageEnglish
Pages (from-to)388-394
Number of pages7
JournalTuberculosis and Respiratory Diseases
Volume55
Issue number4
DOIs
Publication statusPublished - 2003 Jan 1

Fingerprint

Keratin-8
Keratin-18
Keratin-19
Lung Diseases
Lung Neoplasms
Non-Small Cell Lung Carcinoma
Small Cell Lung Carcinoma
Serum
Immunoradiometric Assay
Control Groups
Epitopes
Monoclonal Antibodies
Sensitivity and Specificity

All Science Journal Classification (ASJC) codes

  • Pulmonary and Respiratory Medicine
  • Infectious Diseases

Cite this

Choi, C. M., Kim, W. J., Oh, J. Y., kang, Y., Yoo, C. G., Lee, C. T., ... Shim, Y. S. (2003). Diagnostic Value of Serum Cytokeratin 8, 18 and 19 in Lung Cancer. Tuberculosis and Respiratory Diseases, 55(4), 388-394. https://doi.org/10.4046/trd.2003.55.4.388
Choi, Chang Min ; Kim, Woo Jin ; Oh, Jin Young ; kang, youngae ; Yoo, Chul Gyu ; Lee, Choon Taek ; Kim, Young Whan ; Han, Sung Koo ; Shim, Young Soo. / Diagnostic Value of Serum Cytokeratin 8, 18 and 19 in Lung Cancer. In: Tuberculosis and Respiratory Diseases. 2003 ; Vol. 55, No. 4. pp. 388-394.
@article{ee743e14e7b342a3aa9901a423d75598,
title = "Diagnostic Value of Serum Cytokeratin 8, 18 and 19 in Lung Cancer",
abstract = "Background: Monoclonal antibodies directed against well-known epitopes on cytokeratin (CK) 8, 18 and 19 (Monototal) have been used in the development of a new diagnostic tool for lung cancer. In the mid-1990s, CK 19 fragments (Cyfra 21-1) became popular and widely used for such diagnosis. This is the first study specifically designed to compare these two markers. Method: The serum levels of CK 8, 18 and 19 were measured using two-site monoclonal/polyclonal immunoradiometric assay kit in 57 healthy adults and 289 patients who were admitted to Seoul National University Hospital from May to September, 2002. The lung cancer group comprised 129 primary lung cancer patients; 116 with non-small cell lung cancer(NSCLC) and 13 with small cell lung cancer (SCLC). The control group comprised 160 non-malignant pulmonary lung disease patients and 57 healthy adults. A total of 166 twin Monototal and Cyfra 21-1 serum assays were obtained; 76 with lung cancer, 70 with non-malignant pulmonary lung disease and 20 healthy adults. Results: The mean serum value of Monototal was 412.47 ± 455.45U/L in NSCLC, 237.08 ± 145.15U/L in SCLC, 126.54 ± 95.72U/L in non-malignant pulmonary lung disease, and 63.68 ± 31.66U/L in healthy adults. The serum values of the lung cancer groups were significantly higher than those of the control group (p < 0.01). Using a cut off value of 188U/L, sensitivity and specificity was 66.4{\%} and 81.9{\%} in NSCLC, and 43.8{\%} and 81.9{\%} in SCLC, respectively. The serum levels of CK 8, 18 and 19 were higher in advanced NSCLC than in early stage disease. Conclusion: The serum levels of CK 8, 18 and 19 may be useful in the diagnosis of NSCLC.",
author = "Choi, {Chang Min} and Kim, {Woo Jin} and Oh, {Jin Young} and youngae kang and Yoo, {Chul Gyu} and Lee, {Choon Taek} and Kim, {Young Whan} and Han, {Sung Koo} and Shim, {Young Soo}",
year = "2003",
month = "1",
day = "1",
doi = "10.4046/trd.2003.55.4.388",
language = "English",
volume = "55",
pages = "388--394",
journal = "Tuberculosis and Respiratory Diseases",
issn = "1738-3536",
publisher = "The Korean Academy of Tuberculosis and Respiratory Diseases",
number = "4",

}

Choi, CM, Kim, WJ, Oh, JY, kang, Y, Yoo, CG, Lee, CT, Kim, YW, Han, SK & Shim, YS 2003, 'Diagnostic Value of Serum Cytokeratin 8, 18 and 19 in Lung Cancer', Tuberculosis and Respiratory Diseases, vol. 55, no. 4, pp. 388-394. https://doi.org/10.4046/trd.2003.55.4.388

Diagnostic Value of Serum Cytokeratin 8, 18 and 19 in Lung Cancer. / Choi, Chang Min; Kim, Woo Jin; Oh, Jin Young; kang, youngae; Yoo, Chul Gyu; Lee, Choon Taek; Kim, Young Whan; Han, Sung Koo; Shim, Young Soo.

In: Tuberculosis and Respiratory Diseases, Vol. 55, No. 4, 01.01.2003, p. 388-394.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Diagnostic Value of Serum Cytokeratin 8, 18 and 19 in Lung Cancer

AU - Choi, Chang Min

AU - Kim, Woo Jin

AU - Oh, Jin Young

AU - kang, youngae

AU - Yoo, Chul Gyu

AU - Lee, Choon Taek

AU - Kim, Young Whan

AU - Han, Sung Koo

AU - Shim, Young Soo

PY - 2003/1/1

Y1 - 2003/1/1

N2 - Background: Monoclonal antibodies directed against well-known epitopes on cytokeratin (CK) 8, 18 and 19 (Monototal) have been used in the development of a new diagnostic tool for lung cancer. In the mid-1990s, CK 19 fragments (Cyfra 21-1) became popular and widely used for such diagnosis. This is the first study specifically designed to compare these two markers. Method: The serum levels of CK 8, 18 and 19 were measured using two-site monoclonal/polyclonal immunoradiometric assay kit in 57 healthy adults and 289 patients who were admitted to Seoul National University Hospital from May to September, 2002. The lung cancer group comprised 129 primary lung cancer patients; 116 with non-small cell lung cancer(NSCLC) and 13 with small cell lung cancer (SCLC). The control group comprised 160 non-malignant pulmonary lung disease patients and 57 healthy adults. A total of 166 twin Monototal and Cyfra 21-1 serum assays were obtained; 76 with lung cancer, 70 with non-malignant pulmonary lung disease and 20 healthy adults. Results: The mean serum value of Monototal was 412.47 ± 455.45U/L in NSCLC, 237.08 ± 145.15U/L in SCLC, 126.54 ± 95.72U/L in non-malignant pulmonary lung disease, and 63.68 ± 31.66U/L in healthy adults. The serum values of the lung cancer groups were significantly higher than those of the control group (p < 0.01). Using a cut off value of 188U/L, sensitivity and specificity was 66.4% and 81.9% in NSCLC, and 43.8% and 81.9% in SCLC, respectively. The serum levels of CK 8, 18 and 19 were higher in advanced NSCLC than in early stage disease. Conclusion: The serum levels of CK 8, 18 and 19 may be useful in the diagnosis of NSCLC.

AB - Background: Monoclonal antibodies directed against well-known epitopes on cytokeratin (CK) 8, 18 and 19 (Monototal) have been used in the development of a new diagnostic tool for lung cancer. In the mid-1990s, CK 19 fragments (Cyfra 21-1) became popular and widely used for such diagnosis. This is the first study specifically designed to compare these two markers. Method: The serum levels of CK 8, 18 and 19 were measured using two-site monoclonal/polyclonal immunoradiometric assay kit in 57 healthy adults and 289 patients who were admitted to Seoul National University Hospital from May to September, 2002. The lung cancer group comprised 129 primary lung cancer patients; 116 with non-small cell lung cancer(NSCLC) and 13 with small cell lung cancer (SCLC). The control group comprised 160 non-malignant pulmonary lung disease patients and 57 healthy adults. A total of 166 twin Monototal and Cyfra 21-1 serum assays were obtained; 76 with lung cancer, 70 with non-malignant pulmonary lung disease and 20 healthy adults. Results: The mean serum value of Monototal was 412.47 ± 455.45U/L in NSCLC, 237.08 ± 145.15U/L in SCLC, 126.54 ± 95.72U/L in non-malignant pulmonary lung disease, and 63.68 ± 31.66U/L in healthy adults. The serum values of the lung cancer groups were significantly higher than those of the control group (p < 0.01). Using a cut off value of 188U/L, sensitivity and specificity was 66.4% and 81.9% in NSCLC, and 43.8% and 81.9% in SCLC, respectively. The serum levels of CK 8, 18 and 19 were higher in advanced NSCLC than in early stage disease. Conclusion: The serum levels of CK 8, 18 and 19 may be useful in the diagnosis of NSCLC.

UR - http://www.scopus.com/inward/record.url?scp=0347754982&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0347754982&partnerID=8YFLogxK

U2 - 10.4046/trd.2003.55.4.388

DO - 10.4046/trd.2003.55.4.388

M3 - Article

AN - SCOPUS:0347754982

VL - 55

SP - 388

EP - 394

JO - Tuberculosis and Respiratory Diseases

JF - Tuberculosis and Respiratory Diseases

SN - 1738-3536

IS - 4

ER -